Merck Beheer

Beheer criteriumcontroles 3/4

De CEO Merck is Rob Davis, benoemd in Apr2021, heeft een ambtstermijn van 3.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 20.27M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde CLP 33.41B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.2 jaar.

Belangrijke informatie

Rob Davis

Algemeen directeur

US$20.3m

Totale compensatie

Percentage CEO-salaris	7.9%
Dienstverband CEO	3.6yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Rob Davis's beloning veranderd ten opzichte van Merck's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

Compensatie versus markt: De totale vergoeding ($USD 20.27M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de CL markt ($USD 5.72M ).

Compensatie versus inkomsten: De vergoeding van Rob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rob Davis (57 yo)

3.6yrs

Tenure

US$20,273,287

Compensatie

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Davis	Chairman	3.6yrs	US$20.27m	0.014% CLP 33.4b
Caroline Litchfield	Executive VP & CFO	3.6yrs	US$8.30m	0.0020% CLP 4.9b
Richard DeLuca	Executive VP & President of Merck Animal Health	13.2yrs	US$6.20m	0.0060% CLP 14.5b
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	15yrs	US$6.24m	0.0062% CLP 15.1b
Dean Li	Executive VP & President of Merck Research Laboratories	7yrs	US$9.78m	0.0018% CLP 4.4b
Dalton Smart	Senior VP of Finance	less than a year	geen gegevens	0.00018% CLP 436.8m
David Williams	Executive VP and Chief Information & Digital Officer	no data	geen gegevens	0.00079% CLP 1.9b
Peter Dannenbaum	Vice President of Investor Relations	5.3yrs	geen gegevens	geen gegevens
Jennifer Zachary	Executive VP & General Counsel	6.6yrs	US$5.90m	0.0012% CLP 2.8b
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	3.3yrs	geen gegevens	geen gegevens
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Johannes Oosthuizen	Senior VP & President Merck U.S. Human Health	3.8yrs	geen gegevens	0.00094% CLP 2.3b

3.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MRKCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Davis	Chairman	3.3yrs	US$20.27m	0.014% CLP 33.4b
Pamela Craig	Independent Director	9.2yrs	US$400.00k	0.000070% CLP 169.9m
Patricia Russo	Independent Director	29.2yrs	US$360.00k	0.00052% CLP 1.3b
Thomas Glocer	Independent Lead Director	17yrs	US$430.10k	0.00020% CLP 485.3m
Risa Lavizzo-Mourey	Independent Director	4.5yrs	US$365.00k	0.000040% CLP 97.1m
Douglas Baker	Independent Director	2.5yrs	US$347.64k	0.000040% CLP 97.1m
Inge Thulin	Independent Director	6.7yrs	US$340.00k	0% CLP 0
Stephen Mayo	Independent Director	3.7yrs	US$350.00k	0% CLP 0
Kathy Warden	Independent Director	4.7yrs	US$350.00k	0.000020% CLP 48.5m
Christine Seidman	Independent Director	4.7yrs	US$350.00k	0% CLP 0
Paul Rothman	Independent Director	9.2yrs	US$380.00k	0% CLP 0
Mary Coe	Independent Director	5.7yrs	US$342.36k	0% CLP 0

5.2yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MRKCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).

Merck Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Recent updates

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

New minor risk - Share price stability

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$2.14 (vs US$2.35 loss in 2Q 2023)

First quarter dividend of US$0.77 announced

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd